The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

"The Great Healthcare Plan" aims to lower drug costs, reduce premiums, and enhance price transparency, with a focus on Most ...

Despite HCM’s strong genetic basis, patients residing in lower-income or more socially deprived areas faced significantly ...

Reducing liver fat has become a central target in the development of therapies for metabolic dysfunction–associated ...

Standardized monitoring workflows and clearer reimbursement support are critical to improving community clinicians’ readiness ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of ...

Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...

ICHRAs have been growing in popularity, but not without skepticism. While some consumers think they are inferior to ...

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and ...

Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for ...

Retrospective studies show elevated risks, especially for glomerular or proteinuric kidney disease, but absolute risk remains ...